摘要
目的观察每日口服10mg阿托伐他汀对原发性高血压(EH)合并IGT患者炎症因子水平的影响。方法 36例EH合并IGT患者(EH+IGT组)口服阿托伐他汀10mg,1次/晚。另选择36例体检者作为对照(NC)组。检测两组FPG、2hPG、胰岛素抵抗指数(HOMA-IR)及血清炎症因子水平的变化。结果 EH+IGT组均完成试验。口服10 mg阿托伐他汀治疗8周BP、2hPG、HOMA-IR、TNF-α及IL-6均下降[BP(159.71±12.25)/(98.67±12.06)vs(131.89±10.72)/(81.76±9.03)mmHg;2hPG(8.39±0.65)vs(6.76±1.19)mmol/L;HOMA-IR(3.11±1.95)vs(2.30±1.25);TNF-α(32.11±5.36)vs(24.29±4.57)ng/L;IL-6(112.37±24.48)vs(70.47±13.30)ng/L](P<0.01)。结论每日口服10mg阿托伐他汀可降低EH合并IGT患者的血清炎症因子水平。
Objective To study the effects of Atorvastatin 10 mg daily on plasma inflammatory cytokines in hypertension patients with impaired glucose tolerance.Methods A total of 36 EH patients with IGT recieved Atorvastatin 10 mg,qn.36 healthy adults served as controls.The levels of fasting blood glucose,postprandial-2-hour blood glucose,HOMA-IR,inflammatory cytokines of each group were tested before and after treatment.Results All the participants in EH ＋IGT group finished the study.Compared with control group,BP,2hPG,HOMA-IR,TNF-αand IL-6 were decreased significantly[BP（159.71±12.25）/（98.67±12.06）vs（131.89±10.72）/（81.76±9.03）mmHg];2hPG（8.39±0.65）vs（6.76±1.19）mmol/L;HOMA-IR（3.11±1.95）vs（2.30±1.25）;TNF-α（32.11±5.36）vs（24.29±4.57）ng/L;IL-6（112.37±24.48）vs（70.47±13.30）ng/L]（P〈0.01）.Conclusion Atorvastatin 10 mg daily could decrease the level of inflammatory cytokines in hypertension patients with impaired glucose tolerance.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2015年第6期543-545,共3页
Chinese Journal of Diabetes
关键词
阿托伐他汀
原发性高血压
糖耐量异常
肿瘤坏死因子-Α
白细胞介素-6
Atorvastatin
Essential hypertension（EH）
Impaired glucose tolerance（IGT）
Tumor necrosis factor-α（TNF-α）
Interleukin-6（IL-6）
